{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:20:45Z","timestamp":1783362045537,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Der Weg zu pr\u00e4ziseren und innovativen Psychopharmaka ist aufgrund der Komplexit\u00e4t psychischer Erkrankungen und hohen regulatorischen H\u00fcrden m\u00fchsam und langwierig. Dennoch wurden in den letzten Jahren mehrere Medikamente entwickelt und in den USA bzw. der EU zugelassen; sie konnten sich in Deutschland jedoch nicht alle in der Nutzenbewertung durchsetzen. Um sich \u00fcber neue pr\u00e4zisionsmedizinische Ans\u00e4tze sowie Probleme bei der Entwicklung und dem Marktzugang von Psychopharmaka und deren L\u00f6sungsm\u00f6glichkeiten auszutauschen, veranstaltete die Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN) in Kooperation mit House of Pharma &amp; Healthcare am 24.08.2023 den Runden Tisch zur Zukunft der Psychopharmakaforschung in Frankfurt. Teilnehmende aus klinischer Versorgung, akademischer Forschung, Pharmaindustrie und Betroffenenvertretung kamen zusammen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Fragestellung<\/jats:title>\n                    <jats:p>Welche Initiativen sind im Bereich Psychiatrieforschung und Regulatorik notwendig, um Psychopharmaka in Deutschland erfolgreich zu entwickeln und in die Versorgung einbringen zu k\u00f6nnen?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methode<\/jats:title>\n                    <jats:p>Der Beitrag stellt eine Synthese der Vortrags- und Diskussionsbeitr\u00e4ge der eint\u00e4gigen Veranstaltung dar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Aktuelle Herausforderungen liegen darin begr\u00fcndet, dass die biologischen Mechanismen psychischer Erkrankungen komplex und heterogen sind und mit den aktuellen diagnostischen Entit\u00e4ten nur unzureichend abgebildet sind. Die Nutzenbewertung eines Pr\u00e4parates durch den Gemeinsamen Bundesausschuss (G-BA) scheitert oftmals, wenn eine zweckm\u00e4\u00dfige Vergleichstherapie (zVT) nicht sinnvoll ausgew\u00e4hlt oder in einer Studie gepr\u00fcft werden kann. Plattformstudien (APTs), die mehrere Pr\u00e4parate gleichzeitig mit einem Kontrollarm auf ihre Wirksamkeit \u00fcberpr\u00fcfen, k\u00f6nnen das Zulassungsverfahren beschleunigen und sind aussagekr\u00e4ftig. Beratungen durch den G\u2011BA im Vorfeld sollten verbindlich sein. Die Einbindung von Erfahrungsexpertise kann die Psychopharmakaforschung wesentlich bereichern.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerungen<\/jats:title>\n                    <jats:p>Es bedarf eines kontinuierlichen Dialogs zwischen Beh\u00f6rden, Wirtschaft, Wissenschaft, Politik und Betroffenenvertretern, um die Entwicklung und Zulassung von Psychopharmaka voranzutreiben und damit die Lebensqualit\u00e4t von Patientinnen und Patienten zu steigern.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00115-026-01991-2","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:01:34Z","timestamp":1783360894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychopharmakaforschung in Deutschland: Herausforderungen der fr\u00fchen Nutzenbewertung und der Pr\u00e4zisionspsychiatrie","Psychotropic drug research in Germany: challenges of early benefit assessment and precision psychiatry"],"prefix":"10.1007","author":[{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Bielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Broich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Lipinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waltraud","family":"Rinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"R\u00f6seler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Schuier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"von der Goltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Weiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meyer-Lindenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"1991_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/s41591-022-01990-1","volume":"28","author":"CJL Murray","year":"2022","unstructured":"Murray\u00a0CJL (2022) The Global Burden of Disease Study at 30\u00a0years. Nat Med 28:2019\u20132026","journal-title":"Nat Med"},{"key":"1991_CR2","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa052964","volume":"354","author":"MH Trivedi","year":"2006","unstructured":"Trivedi\u00a0MH, Fava\u00a0M, Wisniewski\u00a0SR et\u00a0al (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243\u20131252","journal-title":"N Engl J Med"},{"key":"1991_CR3","unstructured":"Gemeinsamer Bundesausschuss (2026) Nutzenbewertungsverfahren zum Wirkstoff Lecanemab (fr\u00fche Alzheimer-Krankheit). https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/1257\/. Zugegriffen: 22. Apr. 2026"},{"key":"1991_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/HRP.0000000000000396","volume":"32","author":"B Kochanowski","year":"2024","unstructured":"Kochanowski\u00a0B, Kageki-Bonnert\u00a0K, Pinkerton\u00a0EA et\u00a0al (2024) A Review of Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation Combined with Medication and Psychotherapy for Depression. Harv Rev Psychiatry 32:77\u201395","journal-title":"Harv Rev Psychiatry"},{"key":"1991_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s00115-016-0095-z","volume":"87","author":"G Gr\u00fcnder","year":"2016","unstructured":"Gr\u00fcnder\u00a0G (2016) Bedeutung des Arzneimittelmarktneuordnungsgesetzes f\u00fcr die Psychopharmakotherapie. Der Nervenarzt 87:356\u2013366","journal-title":"Der Nervenarzt"},{"key":"1991_CR6","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2023.2479","volume":"67","author":"F Butlen-Ducuing","year":"2024","unstructured":"Butlen-Ducuing\u00a0F, Haberkamp\u00a0M, Aislaitner\u00a0G et\u00a0al (2024) The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers. European Psychiatry 67:e2","journal-title":"European Psychiatry"},{"key":"1991_CR7","doi-asserted-by":"crossref","unstructured":"Butlen-Ducuing F, Silva F, Silva I et\u00a0al. (2024) Applying the EU regulatory framework for the clinical use of psychedelics. The Lancet Psychiatry","DOI":"10.1016\/S2215-0366(24)00203-7"},{"issue":"1-3","key":"1991_CR8","first-page":"19","volume":"21","author":"WPS Horan","year":"2024","unstructured":"Horan\u00a0WPS, Velligan\u00a0G, Davis\u00a0DI, Keefe\u00a0M, Khin\u00a0RS, Butlen-Ducuing\u00a0NA, Harvey\u00a0F, Horan\u00a0PD (2024) Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways Forward. Innov Clin Neurosci 21(1-3):19\u201319","journal-title":"Innov Clin Neurosci"},{"key":"1991_CR9","unstructured":"Verband Forschender Arzneimittelhersteller e.\u202fV. (2024) EU implementing regulation on the EU HTA process with room for improvement. https:\/\/www.vfa.de\/de\/wirtschaft-politik\/euro-hta\/eu-hta-process. Zugegriffen: 26. Apr. 2026"},{"key":"1991_CR10","unstructured":"Verband Forschender Arzneimittelhersteller e.\u202fV. (2025) Leichte Erholung der Studienaktivit\u00e4t in Deutschland. https:\/\/www.vfa.de\/de\/forschung-entwicklung\/forschungsstandort-deutschland\/klinische-studien-deutschland.html. Zugegriffen: 26. Apr. 2026"},{"key":"1991_CR11","unstructured":"Verband Forschender Arzneimittelhersteller e.\u202fV. (2022) \u00c4nderung der zweckm\u00e4\u00dfigen Vergleichstherapie. https:\/\/www.vfa.de\/de\/wirtschaft-politik\/amnog\/zweckmaessige-vergleichstherapie. Zugegriffen: 26. Apr. 2026"},{"key":"1991_CR12","doi-asserted-by":"crossref","unstructured":"R\u00e9muzat C, Urbinati D, Mzoughi O et\u00a0al. (2015) Overview of external reference pricing systems in Europe. J\u00a0Mark Access Health Policy\u00a03","DOI":"10.3402\/jmahp.v3.27675"},{"key":"1991_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","volume":"18","author":"DC Angus","year":"2019","unstructured":"Angus\u00a0DC, Alexander\u00a0BM, Berry\u00a0S et\u00a0al (2019) Adaptive platform trials: definition, design, conduct and reporting considerations. Nature Reviews Drug Discovery 18:797\u2013807","journal-title":"Nature Reviews Drug Discovery"},{"key":"1991_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"J Woodcock","year":"2017","unstructured":"Woodcock\u00a0J, LaVange\u00a0LM (2017) Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med 377:62\u201370","journal-title":"N Engl J Med"},{"key":"1991_CR15","unstructured":"Nuffield Department of Population Health (2024) RECOVERY Trial. https:\/\/www.recoverytrial.net. Zugegriffen: 26. Apr. 2026"},{"key":"1991_CR16","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman\u00a0JA, Stroup\u00a0TS, McEvoy\u00a0JP et\u00a0al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"1991_CR17","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1056\/NEJMoa052963","volume":"354","author":"AJ Rush","year":"2006","unstructured":"Rush\u00a0AJ, Trivedi\u00a0MH, Wisniewski\u00a0SR et\u00a0al (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231\u20131242","journal-title":"N Engl J Med"},{"key":"1991_CR18","unstructured":"IQWIG (2023) Esketamin (therapieresistente Major Depression): Nutzenbewertung gem\u00e4\u00df \u00a7\u00a035a\u00a0SGB\u00a0V. https:\/\/www.iqwig.de\/download\/a23-18_esketamin_nutzenbewertung-35a-sgb-v_v1-0.pdf. Zugegriffen: 26. Apr. 2026"},{"key":"1991_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2022.110520","volume":"116","author":"A Mokhtari","year":"2022","unstructured":"Mokhtari\u00a0A, Porte\u00a0B, Belzeaux\u00a0R et\u00a0al (2022) The molecular pathophysiology of mood disorders: From the analysis of single molecular layers to multi-omic integration. Progress in Neuro-Psychopharmacology and Biological Psychiatry 116:110520","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"1991_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/wps.21078","volume":"22","author":"A Abi-Dargham","year":"2023","unstructured":"Abi-Dargham\u00a0A, Moeller\u00a0SJ, Ali\u00a0F et\u00a0al (2023) Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry 22:236\u2013262","journal-title":"World Psychiatry"},{"key":"1991_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105159","volume":"149","author":"D Cavaleri","year":"2023","unstructured":"Cavaleri\u00a0D, Moretti\u00a0F, Bartoccetti\u00a0A et\u00a0al (2023) The role of BDNF in major depressive disorder, related clinical features, and antidepressant treatment: Insight from meta-analyses. Neurosci Biobehav Rev 149:105159","journal-title":"Neurosci Biobehav Rev"},{"key":"1991_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73918-z","volume":"10","author":"H Erabi","year":"2020","unstructured":"Erabi\u00a0H, Okada\u00a0G, Shibasaki\u00a0C et\u00a0al (2020) Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis. Sci Rep 10:16822","journal-title":"Sci Rep"},{"key":"1991_CR23","doi-asserted-by":"crossref","unstructured":"Orsolini L, Pompili S, Tempia Valenta S et\u00a0al. (2022) C\u2011Reactive Protein as a\u00a0Biomarker for Major Depressive Disorder? Int J Mol Sci\u00a023","DOI":"10.3390\/ijms23031616"},{"key":"1991_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/164_2020_396","volume":"271","author":"SD Clark","year":"2022","unstructured":"Clark\u00a0SD (2022) The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach. Handb Exp Pharmacol 271:525\u2013546","journal-title":"Handb Exp Pharmacol"},{"key":"1991_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1515\/biol-2021-0001","volume":"16","author":"X Kang","year":"2021","unstructured":"Kang\u00a0X, Tang\u00a0H, Liu\u00a0Y et\u00a0al (2021) Research progress on the mechanism of orexin in pain regulation in different brain regions. Open Life Sciences 16:46\u201352","journal-title":"Open Life Sciences"},{"key":"1991_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/bph.12415","volume":"171","author":"J Li","year":"2014","unstructured":"Li\u00a0J, Hu\u00a0Z, de Lecea\u00a0L (2014) The hypocretins\/orexins: integrators of multiple physiological functions. Br J Pharmacol 171:332\u2013350","journal-title":"Br J Pharmacol"},{"key":"1991_CR27","first-page":"251","volume":"16","author":"ME Hirschtritt","year":"2018","unstructured":"Hirschtritt\u00a0ME, Insel\u00a0TR (2018) Digital Technologies in Psychiatry: Present and Future. Focus (Am Psychiatr Publ) 16:251\u2013258","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"1991_CR28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S2215-0366(15)00579-9","volume":"3","author":"LM Williams","year":"2016","unstructured":"Williams\u00a0LM (2016) Precision psychiatry: a\u00a0neural circuit taxonomy for depression and anxiety. Lancet Psychiatry 3:472\u2013480","journal-title":"Lancet Psychiatry"},{"key":"1991_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(09)60329-9","volume":"374","author":"I Chalmers","year":"2009","unstructured":"Chalmers\u00a0I, Glasziou\u00a0P (2009) Avoidable waste in the production and reporting of research evidence. Lancet 374:86\u201389","journal-title":"Lancet"},{"key":"1991_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-018-0087-1","volume":"4","author":"V Minogue","year":"2018","unstructured":"Minogue\u00a0V, Cooke\u00a0M, Donskoy\u00a0AL et\u00a0al (2018) Patient and public involvement in reducing health and care research waste. Research Involvement and Engagement 4:5","journal-title":"Research Involvement and Engagement"},{"key":"1991_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4738","volume":"363","author":"JC Crocker","year":"2018","unstructured":"Crocker\u00a0JC, Ricci-Cabello\u00a0I, Parker\u00a0A et\u00a0al (2018) Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. BMJ 363:k4738","journal-title":"BMJ"},{"key":"1991_CR32","unstructured":"Steinbeck V, Ernst S\u2011C, Pross C (2021) Patient-Reported Outcome Measures (PROMs): Ein internationaler Vergleich. In: Bertelsmann Stiftung (ed), G\u00fctersloh"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01991-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-01991-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01991-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:01:53Z","timestamp":1783360913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-026-01991-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":32,"alternative-id":["1991"],"URL":"https:\/\/doi.org\/10.1007\/s00115-026-01991-2","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Meyer-Lindenberg: Beraterhonorare 2025: Heinrich-Lanz-Stiftung, ECNP, Johnson&Johnson, Hector Stiftung, Helmut-Horten-Stiftung, Lundbeckfonden, Wellcome Trust, Clarivate, The LOOP Z\u00fcrich, PEPR-INSERM. Autorenhonorare: 2025: PSY (Psychiatrie und Psychotherapie Update Refresher, FOMF), Consorcio Mexicano de Neuropsicofarmacolog\u00eda (MCNP), Med. Universit\u00e4t Wien, Universit\u00e4t Norwalk\/USA, Vitos Kliniken Eltville. A.\u00a0Reif: has received honoraria for lectures and\/or advisory boards from Janssen\/Johnson & Johnson, Boehringer Ingelheim, Compass, GH Research, SAGE\/Biogen, LivaNova, Medice, Shire\/Takeda, Newron, MSD, AbbVie, cyclerion and Polpharma. Also, he has received research grants from Medice and Janssen. M.\u00a0Schuier: Zur Zeit des Treffens und Erstellung des Dokuments: Mitarbeiter und Aktienhalter von Johnson & Johnson; Aktuell: Mitarbeiter und Aktienhalter der Novartis Pharma AG. H.\u00a0Bielen: Biogen GmbH (Angestelltenverh\u00e4ltnis). A.\u00a0R\u00f6seler: Biogen GmbH (Angestelltenverh\u00e4ltnis). C.\u00a0von der Goltz: Mitarbeiter von Boehringer Ingelheim International GmbH. M.\u00a0Weiland: angestellt bei J&J. G.\u00a0Gr\u00fcnder war in den letzten drei Jahren als Berater f\u00fcr AbbVie (Chicago, USA), Beckley Psytech (London, UK), Boehringer Ingelheim (Ingelheim, Deutschland), Bristol-Myers Squibb (Princeton, USA), das Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG, K\u00f6ln, Deutschland), Johnson & Johnson (New Brunswick, USA), Lundbeck (Kopenhagen, D\u00e4nemark), MindMed (New York, USA), Otsuka (Chiyoda, Japan), Roche (Basel, Schweiz) und ROVI (Madrid, Spanien) t\u00e4tig. Er war als Referent f\u00fcr Johnson & Johnson, Lundbeck, Otsuka und ROVI t\u00e4tig. Er erhielt Forschungsunterst\u00fctzung von Beckley Psytech, Boehringer Ingelheim und MindMed. Er ist Mitgr\u00fcnder und\/oder Gesellschafter der Mind and Brain Institute GmbH (Zornheim, Deutschland), der OVID Health Systems GmbH, der OVID Clinic Berlin GmbH, der OVID Beteiligungsgesellschaft mbH, der OVID Tagesklinik GmbH & Co. KG und der MIND Foundation gGmbH (Berlin, Deutschland). W.\u00a0Rinke, K.\u00a0Broich und S.\u00a0Lipinski, geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}